Echo IQ Seeks FDA Clearance for Heart Solution

EchoIQ Limited (AU:EIQ) has released an update.

Echo IQ Limited has initiated a pre-submission meeting request with the US FDA for its heart failure clinical decision support solution, EchoSolv HF, which has shown promising results in recent studies. The AI technology demonstrated an 86% detection rate of heart failure cases, significantly outperforming standard clinical practice. This strategic move aims to secure FDA clearance by the second half of 2025, tapping into the lucrative US$60 billion heart failure market.

For further insights into AU:EIQ stock, check out TipRanks’ Stock Analysis page.